GABA deficiency in NF1 A multimodal [11C]-flumazenil and spectroscopy study by Violante, Inês R. et al.
Inês R. Violante, PhD
Miguel Patricio, PhD
Inês Bernardino, PhD
José Rebola, PhD
Antero J. Abrunhosa,
PhD
Nuno Ferreira, PhD
Miguel Castelo-Branco,
MD, PhD
Correspondence to
Dr. Violante:
i.violante@imperial.ac.uk
Supplemental data
at Neurology.org
GABA deficiency in NF1
A multimodal [11C]-flumazenil and spectroscopy study
ABSTRACT
Objective: To provide a comprehensive investigation of the g-aminobutyric acid (GABA) system in
patients with neurofibromatosis type 1 (NF1) that allows understanding the nature of the GABA
imbalance in humans at pre- and postsynaptic levels.
Methods: In this cross-sectional study, we employed multimodal imaging and spectroscopy meas-
ures to investigate GABA type A (GABAA) receptor binding, using [11C]-flumazenil PET, and GABA
concentration, using magnetic resonance spectroscopy (MRS). Fourteen adult patients with NF1
and 13 matched controls were included in the study. MRS was performed in the occipital cortex
and in a frontal region centered in the functionally localized frontal eye fields. PET and MRS
acquisitions were performed in the same day.
Results: Patients with NF1 have reduced concentration of GABA1 in the occipital cortex (p 5
0.004) and frontal eye fields (p 5 0.026). PET results showed decreased binding of GABAA
receptors in patients in the parieto-occipital cortex, midbrain, and thalamus, which are not ex-
plained by decreased gray matter levels.
Conclusions: Abnormalities in the GABA system in NF1 involve both GABA concentration and
GABAA receptor density suggestive of neurodevelopmental synaptopathy with both pre- and
postsynaptic involvement. Neurology® 2016;87:897–904
GLOSSARY
BOLD 5 blood oxygen level–dependent; BP 5 binding potential; FEF 5 frontal eye field; GABA 5 g-aminobutyric acid;
GABAA5 g-aminobutyric acid type A;GM5 gray matter;MNI5Montreal Neurological Institute;MRS5magnetic resonance
spectroscopy; NAA 5 N-acetylaspartate; NAAG 5 N-acetylaspartylglutamine; NF1 5 neurofibromatosis type 1; ROI 5
region of interest; WM 5 white matter.
Neurofibromatosis type 1 (NF1) is a neurodevelopmental monogenetic disorder, characterized by
multisystemic symptoms, including increased incidence of cognitive deficits (50%–70%)1 and
predisposition for tumor development.2 Cognitive impairments occur even in the absence of visible
brain alterations, suggesting the existence of pathophysiologic abnormalities at a finer scale.
One hypothesis to explain the cognitive and behavioral profile is based on neurochemical
imbalance in the g-aminobutyric acid (GABA) system. Evidence for it includes (1) cellular and
molecular studies in the Nf11/2 model, which established a connection between RAS regulation
by the NF1 gene, GABAergic signaling, and learning deficits3,4; and (2) in vivo magnetic reso-
nance spectroscopy (MRS) studies in children with NF1 showing reduced GABA levels.5,6
Moreover, it is possible that GABAergic alterations influence the distribution or binding
affinity of GABA receptors, consistent with the “GABA shift.”7 This model postulates that
increased GABA levels enhance the affinity of GABA type A (GABAA) receptors for benzodi-
azepine ligands. The directionality of changes in disease is, however, difficult to predict. On
one hand, in homeostatic systems, the natural prediction is that, to maintain efficient
From the Institute for Biomedical Imaging and Life Sciences, Faculty of Medicine (I.R.V., M.P., I.B., J.R., M.C.-B.), Laboratory of Biostatistics and
Medical Informatics, Faculty of Medicine (M.P., M.C.-B.), and Institute of Nuclear Sciences Applied to Health (A.J.A., N.F., M.C.-B.), University
of Coimbra, Portugal; and Division of Brain Sciences (I.R.V.), Department of Medicine, Hammersmith Hospital Campus, Imperial College
London, UK.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was paid by the Wellcome Trust.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
© 2016 American Academy of Neurology 897
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
neurotransmission, low GABA levels lead to
increasing numbers of GABA receptors. On
the other hand, reduced GABA concentration
in patients could reflect a compensatory mech-
anism to counterbalance pre- and postsynap-
tically the effects of increased GABA release
caused by reduced neurofibromin expression.4
GABA metabolism can be downregulated as
a response to increased GABAergic neuro-
transmission, thus limiting GABA availability
for packaging and release.8 If this were the
case, we expect observing low GABA levels
accompanied by a reduction in the number
of GABA receptors. To further characterize
the GABA system in adults with NF1, we
studied the distribution of GABAA receptors
using [11C]-flumazenil PET, and GABA con-
centration using MRS.
METHODS Participants. We performed a cross-sectional
study in 14 adult patients with NF1, diagnosed by the NIH
criteria,9 and 14 healthy controls, matched for age, sex, and
educational level. All participants were right-handed.
Exclusion criteria included psychiatric disorder, neurologic
illness affecting brain function other than NF1, IQ ,75, epi-
lepsy, traumatic brain injury, or a clinically significant intracranial
abnormality detected on MRI. T2 hyperintensities (commonly
found in NF1) were not considered an exclusion criterion for
patients. However, if present within the voxels prescribed for
spectroscopy, the correspondent spectrum was not included.
Our final cohort comprised 14 patients with NF1 (mean age
34.7 6 7.1 years, 4 males) and 13 matched controls (mean age
36 6 8.9 years, 4 males) (table 1).
None of the participants were taking medication. Three pa-
tients reported taking antidepressants in the past (for periods
ranging between 6 months to 3 years), but none were medicated
in the year before the study. One control was medicated with
antidepressants and stopped the medication a month before tak-
ing part in the study. None of the participants were ever medi-
cated with anticonvulsants. Participants were instructed to
withhold from drinking alcohol 24 hours before testing and from
smoking or drinking coffee on the day of testing. All participants
scored below the cutoff (,8) defined for hazardous and harmful
alcohol use in the AUDIT (Alcohol Use Disorders Identification
Test).10,11 Groups did not significantly differ in their scores (NF1:
2.07 6 1.69; controls: 2.85 6 2.54; t25 5 0.939, p 5 0.36).
Neuropsychological testing. IQ was assessed using the Portu-
guese version of the Wechsler Adult Intelligence Scale–III.12 Pa-
tients with NF1 had IQ values in the normal range but
significantly lower than controls (independent-samples t tests;
Total IQ, p 5 0.002; Performance IQ, p , 0.001; Verbal IQ,
p 5 0.030).
Imaging. Participants underwent all imaging acquisitions in the
same day. PET and MRI order was counterbalanced. MRS was
performed in the occipital cortex, to investigate whether GABA
deficits persist into adulthood, and the frontal eye fields (FEFs).
The latter was chosen because of its numerous cortical inhibitory
circuits and because its location is easily identified using a func-
tional localizer.
MRI and MRS acquisitions. Scanning was performed using
a 3T Tim Trio (Siemens, Erlangen, Germany) with a 12-channel
head coil. Acquisitions were as follows: (1) T1-weighted
magnetization-prepared rapid-acquisition gradient echo for vox-
el placement and volumetric measurements; (2) T2-weighted
fluid-attenuated inversion recovery to identify T2 hyper-
intensities; (3) functional localizer for the FEF using single-shot
echo planar imaging. Participants performed an oculomotor
task as described in the e-Methods at Neurology.org. Individual
brain activation was examined using Neuro3D (Siemens) to allow
immediate placement of the MRS voxel. (4) 2xGABA-edited
spectra, MEGA-PRESS method.13 The occipital voxel was posi-
tioned within the occipital cortex with its lower face aligned with
the cerebellar tentorium (figure 1A and figure e-1 for position
across all participants). The FEF voxel was positioned based on
the blood oxygen level–dependent (BOLD) activation elicited by
the functional localizer (figure 1B and figure e-1 for position
across all participants). In 2 NF1 participants, the voxel was
placed according to anatomical landmarks (junction of precentral
sulcus and superior frontal sulcus) because of insufficient BOLD
activation. All voxels were placed on the right FEF with the
exception of 2 participants who showed a lateralization of the FEF
activation to the left hemisphere (2 patients with NF1). (5) 1H-
PRESS in the occipital and FEF positions. Detailed scan measures
can be found in the e-Methods.
MRI volumetric analyses. T1-weighted images were seg-
mented using the VBM8 toolbox (http://dbm.neuro.uni-jena.de/
vbm/) in SPM8 (http://www.fil.ion.ucl.ac.uk/spm) to determine
the relative proportions of gray matter (GM), white matter (WM),
and CSF. This was used to determine tissue proportions in the
spectroscopic voxels using Matlab7 (The MathWorks Inc., Natick,
MA) and to perform voxel-based morphometry (e-Methods). The
latter was used to investigate the potential confound that group
differences in [11C]-flumazenil binding could partially arise from
counterpart differences in GM volume.14
fMRI analyses. Data processing and analysis were performed
in BrainVoyager QX2.3 (Brain Innovation, Maastricht, the
Netherlands). Preprocessing included slice time correction, linear
trend removal, temporal high-pass filtering (3 cycles per run),
Table 1 Demographics and neuropsychological testing performance
NF1 Controls p Value
Demographics
No. of participants 14 13
Age, y, mean 6 SD 34.7 6 7.1 36 6 8.9 0.697
Sex, female/male 10/4 9/4 0.901
Years of education 11.4 6 4.5 13.7 6 3.5 0.160
Handedness, R/L 14/0 13/0
Neuropsychological
WAIS-III
Total IQ 99.5 6 13.7 116.15 6 11.8 0.002a
Performance IQ 99.1 6 13.5 119.3 6 12.2 ,0.001a
Verbal IQ 100.2 6 12.5 111.3 6 12.6 0.030
Abbreviations: NF1 5 neurofibromatosis type 1; WAIS-III 5 Wechsler Adult Intelligence
Scale–III.
Performance data are presented as means 6 SD.
aSignificant results after correcting for multiple comparisons using the Holm-Sídák method
(a 5 0.05).
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motion correction, and spatial smoothing (full width at half
maximum 5-mm gaussian kernel). No participant had within-run
movements.3 mm. Predictors for the general linear model were
built by convolving a boxcar time course with a 2-gamma func-
tion. BOLD signal peak amplitude (% signal change) for the pro-
and antisaccade contrasts, at the peak voxel, were extracted for
each participant in the FEF and occipital regions.
MRS analyses. MEGA-PRESS. The signal detected at 3.02
ppm is known to contain contributions from both macromole-
cules and homocarnosine,15 and is therefore referred to as
GABA1. Quantification of GABA1 (figure 1B) was performed
using the Gannet 2.0 toolkit16 to yield a GABA1/H2O ratio
(institutional units). Only spectra with relative fit error ,15%
were included. Based on this criterion, the FEF spectra from 2
controls and 4 NF1s were excluded. For one control, the FEF
spectrum was not acquired because of technical difficulties.
Therefore, we included data from the FEFs of 10 controls and
9 patients. For the occipital voxel, we included data from 12
controls and 14 patients as one control was identified as an outlier
(upper fence/hinge) and excluded from the analysis.
To account for differences in voxel tissue composition, the
voxel fraction of WM (fWM) and GM (fGM) was used to normal-
ize the GABA1 concentration according to: GABA1corr 5
GABA1/(fWM 1 fGM).
PRESS. LCModel software (version 6.3) was used for
metabolite quantification applying the internal water reference
method, accounting for different water content in GM, WM,
and CSF.17 Only metabolites with Cramér–Rao bounds
,20% were considered. Concentrations of N-acetylaspartate
(NAA) plusN-acetylaspartylglutamine (NAAG), creatine plus phos-
phocreatine, glycerophosphocholine, myo-inositol, glutamate, and
glutamine were included for analysis. Concentrations in millimole
units were calculated for all metabolites and results are presented in
institutional units.
[11C]-Flumazenil PET. A Philips Gemini GXL scanner
(Philips Medical Systems, Best, the Netherlands) was used to
acquire a CT scan and 26 sequential 3-dimensional PET
frames of the entire brain (90 slices, 2-mm slice sampling), over
a period of 60 minutes, after the bolus injection of 584.66 25.9
MBq [11C]-flumazenil. PET data were reconstructed using
a LOR-RAMLA algorithm. Voxel-by-voxel binding potential
(BP) was calculated from dynamic PET images using the basis
function implementation of the Simplified Reference Tissue
Model, with the pons as reference.18,19 Several studies showed that
using the pons activity as a reference is reliable and highly cor-
related with the BP values estimated by the arterial sampling
method.20 Moreover, to ensure that systematic differences in the
pons time-activity curves did not affect the results, we compared
standard uptake values in the pons between the 2 groups (inde-
pendent-samples, t25 5 0.370, p 5 0.714).
PET data were normalized to Montreal Neurological Insti-
tute (MNI) space after rigidly coregistering the individual PET
scan to the participant anatomical T1 scan in SPM8. The latter
were segmented using the unified segmentation method21 in
order to extract the transformation map into MNI space. This
was then used to nonlinearly warp the PET scans. The resulting
normalized images were smoothed using an isotropic gaussian
kernel (12 mm full width at half maximum).
We performed exploratory whole-brain and region-of-interest
(ROI)-based analyses. Whole-brain group differences were evalu-
ated in SPM8 using independent-samples t test. [11C]-Flumazenil
BP differences were considered statistically significant at peak
height threshold of uncorrected p , 0.005 with cluster size
greater than 230 contiguous voxels, which corresponds to
a threshold of p , 0.05 corrected by cluster level for multiple
comparisons as estimated by 10,000 Monte Carlo simulations in
3dClustSim (AFNI, http://afni.nimh.nih.gov/afni/). ROI-based
analyses were performed in regions used for spectroscopy. The
mean BP at these voxels was determined with the objective of
investigating the relation between GABA concentration and
GABAA BP.
Statistical analyses. Data were transferred to SPSS version 21
(IBM Corp., Armonk, NY) for analysis. All dependent variables
were tested for normality of distribution using the Shapiro-Wilk
Figure 1 Magnetic resonance spectroscopy measurements
Localization of the magnetic resonance spectroscopy voxel (yellow square) in the visual cor-
tex (A) and FEF as localized with a functional localizer (B). (C) Edited magnetic resonance
spectroscopy spectrum from a representative participant showing clearly resolved peaks
for GABA1 and glutamine 1 glutamate (Glx). The inset on the right shows the fit output
for the GABA1 signal. MEGA-PRESS spectra were processed using the Gannet 2.0 toolkit,
the green line shows the raw GABA data, the blue line the postphase and frequency aligned
GABA data, and the black line is the residual difference between the experimental data and
the curve fit. (D) Single-voxel–localized PRESS spectrum (blue line) from a representative
participant with spectral fits (red line) and the residual difference between the experimental
data and the curve fit (black line) determined using LCModel. Cr5 creatine; FEF5 frontal eye
field; GABA 5 g-aminobutyric acid; Gln 5 glutamine; Glu 5 glutamate; GPC 5 glycerophos-
phocholine; mI5myo-inositol; PCr5 phosphocreatine; tNAA5 totalN-acetylaspartate (NAA
[N-acetylaspartate] 1 NAAG [N-acetylaspartylglutamine]).
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test and for outliers using the Tukey method. All variables were
normally distributed.
Group differences were evaluated using independent-samples
t tests and corrected for multiple comparisons using the Holm-Sídák
method (a 5 0.05). ROI analyses were performed using
independent-samples t test and Pearson correlations (robustness
estimated using bootstrapping, 10,000 iterations, to provide 95%
confidence intervals). Effect sizes were calculated using Cohen d.
Variance was similar between the groups as tested using the Levene
test of homogeneity of variances.
Standard protocol approvals, registrations, and patient
consents. Study procedures were reviewed and approved by the
Ethics Commission of the Faculty of Medicine of the University
of Coimbra. Participants provided written informed consent.
RESULTS MRS results. Patients with NF1 displayed
decreased GABA1 levels, of on average 11.5%, in
the occipital cortex (t24 5 3.172, p 5 0.004, d 5
1.14) and 22% in the FEF (t17 5 2.443, p 5 0.026,
d 5 1.27) (figure 2). In addition, patients showed
lower levels of NAA 1 NAAG (t25 5 3.361, p 5
0.002, d 5 1.31; 12% reduction) and glutamate
(t25 5 2.787, p 5 0.01, d 5 1.08; 10% reduction)
in the occipital cortex (figure 2). A full summary of
the spectroscopy results can be found in table e-1.
PET results.Whole-brain voxel-based analyses indicated
that patients with NF1 have decreased [11C]-flumazenil
BP in a left parieto-occipital region that encompasses
the precuneus (MNI coordinatesPeak voxel: [222 260
30]; z score 5 3.65, k 5 381, p , 0.05 corrected,
d 5 1.89) and in a region that includes the left
midbrain and thalamus (MNI coordinatesPeak voxel:
[22 234 210]; z score 5 2.95, k 5 447, p , 0.05
corrected, d 5 1.64), whereas no brain regions
displayed increased BP in patients (figure 3).
Moreover, VBM showed that decreased [11C]-
flumazenil BP in patients is not explained by
decreased GM content, as decreased GM and
decreased BP in patients do not colocalize (figure
e-2). Moreover, to ensure that PET results were
not hindered by concomitant abnormalities in
GM, we performed correlation analyses between
GM density and BP in the regions showing
decreased PET BP. No correlation was observed
for patients or controls (e-Methods), confirming
that decreased BP in patients is not explained by
GM alterations.
ROI-based analysis for the occipital and FEF
voxels showed no statistically significant group
differences in BP (occipital: t25 5 0.519, p 5
0.608, d 5 0.20; FEF: t24 5 0.936, p 5 0.359,
d 5 0.37).
Cross-modality correlations. The relationship between
the density of GABAA receptors and the concentra-
tion of GABA was examined in occipital and FEF
voxels. In patients, the concentration of GABA1
was negatively correlated with the density of GABAA
receptors in the FEF (r520.842, p5 0.004, n5 9,
95% confidence interval 5 21.000 to 20.368) but
Figure 2 Magnetic resonance spectroscopy alterations in patients with NF1
Metabolites showing differences between patients with NF1 (green) and controls (gray) in the occipital cortex and the FEF. The triangle shape indicates
a patient with NF1 in whom GABA1 was measured in the left hemisphere and the white-filled circle represents a patient in whom the FEF location was
determined using anatomical landmarks. Graphs depict individual values, mean, and SD. FEF 5 frontal eye field; GABA 5 g-aminobutyric acid; Glu 5
glutamate; NAA 5 N-acetylaspartate; NF1 5 neurofibromatosis type 1.
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not in the occipital cortex (r 5 20.211, p 5 0.469,
n 5 14) (figure 4). In controls, we did not find any
significant correlation, neither in the FEF (r 5
20.342, p 5 0.334, n 5 10) nor in the occipital
cortex (r 5 0.013, p 5 0.969, n 5 12). Yet, given
the correlation values in the FEF and the low sample
size, it is possible that the absence of significance is
attributable to a type II error.
Finally, we examined whether individual peak
BOLD amplitudes elicited by the oculomotor task
were related with GABA concentration or GABAA
BP. There was no significant correlation between
either GABAA BP or GABA1 in neither the FEF
nor occipital cortex for any of the groups.
DISCUSSION We report a comprehensive study of
the GABA system in patients with NF1 that investi-
gated cortical GABA concentration using MRS and
GABAA receptor density using PET imaging. Our
results indicate that patients with NF1 have decreased
GABA1 levels and decreased GABAA receptors, cor-
roborating our hypothesis that alterations in the
GABA system extend beyond reduced GABA
concentration.
Spectroscopy results showed that reduced GABA
levels in the occipital cortex persist into adulthood,
confirming our initial findings in children with
NF1,5,6 and that this pattern is additionally observed
in a frontal region centered in the FEF. Altogether,
the observation of reduced GABA levels in several
cortical locations (medial frontal cortex,5 occipital,
and FEF) suggests a ubiquitous cortical dysfunction.
Moreover, in the occipital cortex, GABA reductions
were accompanied by lower glutamate and NAA 1
NAAG concentrations. This reduction in NAA is in
agreement with earlier reports in subcortical struc-
tures22,23 and WM.24 The fact that both glutamate
and NAA are altered might be explained by the tight
link between these metabolites; they are intercon-
nected through a series of biochemical reactions,
mainly the tricarboxylic acid cycle and glutamate–
glutamine cycle.25 It is therefore likely that reduced
levels of GABA, glutamate, and NAA are linked and
contributing to maintaining low levels of GABA
available for neurotransmission. Furthermore, our
results are in agreement with recent findings in the
Nf11/2 model showing GABAergic and glutamater-
gic alterations.26
GABAA receptor density was also found to be
reduced in patients in discrete locations: parieto-
occipital cortex, midbrain, and thalamus. Alterations
in the parieto-occipital cortex are in agreement with
functional27,28 and anatomical29,30 abnormalities re-
ported in NF1. Likewise, thalamic metabolic31–33
and volumetric alterations30 have been previously re-
ported. Both the thalamus and midbrain are impor-
tant relay stations of sensory inputs to the cortex.
GABAergic neurons in the thalamus are involved in
the generation of synchronized activity in thalamo-
cortical networks,34 a critical process for cognitive
functions. In the midbrain, GABAergic neurons are
involved in controlling the firing pattern of dopami-
nergic neurons.35
Of note, PET results were not hindered by con-
comitant abnormalities in GM. It is advisable that
studies investigating differences in GABAA density
using flumazenil perform GM comparisons indepen-
dently, as the relationship between flumazenil BP and
GM volume36 or cortical thickness14 is not homoge-
neous across brain regions. VBM results showed that
decreased BP and decreased GM density do not
Figure 3 [11C]-Flumazenil PET binding differences between patients with NF1
and controls
Areas showing decreased [11C]-flumazenil binding in patients (contrast control . NF1, p ,
0.05 corrected). NF1 5 neurofibromatosis type 1.
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colocalize and are not correlated, indicating that
decreased GM does not explain decreased density of
GABAA receptors. Of note, we found that increased
GM volume and decreased [11C]-flumazenil BP in
patients colocalizes, in a region including left mid-
brain and left thalamus. Here, GM volume is
enlarged in the absence of a parallel increase in inhib-
itory neurons. This could either be an indication of
increased populations of other neuronal types,
namely, dopaminergic and glutamatergic, or that
the population of inhibitory neurons preferentially
expresses other types of GABA receptors. Studies with
PET ligands to other receptors or postmortem studies
could disentangle this hypothesis.
Our findings revealed a complex pattern of alter-
ations in the GABA system in NF1, with both
GABA1 and GABAA reductions, yet in different
locations. In addition, a negative correlation
between GABA1 and the density of GABAA recep-
tors was observed in the FEF of patients and not in
the occipital cortex. The fact that this relationship
was not observed in controls is an indication that
natural variation is not tightly linked for these 2
variables.
It is important to note that MRS and PET are
complementary techniques measuring different com-
ponents of the GABA system and it is possible that
different brain regions give primacy to different regu-
latory mechanisms. Studies measuring GABA1 in
regions showing altered GABAA binding could help
disentangle the hypothesis that a reduction in both
GABA levels and GABAA receptors can occur as part
of a regulatory mechanism to deal with the detrimen-
tal effects of increased GABAergic neurotransmission.
Finally, it is noteworthy that both GABA MRS
and [11C]-flumazenil PET are subject to limitations.
Particularly important to this study is the fact that
MRS is not capable of distinguishing between meta-
bolic and synaptic pools, and [11C]-flumazenil PET is
not specific for the synaptic subtypes of the GABAA
benzodiazepine receptor, as it shows affinity to both
synaptic and extrasynaptic receptor subtypes.37
Overall, we now have evidence of alterations
occurring at multiple levels of the GABA pathway.
Studies in animal models have shown presynaptic al-
terations that lead to increase GABA release,4,26 while
our studies in humans show that the overall concen-
tration of GABA is reduced as well as the expression
of GABAA receptors. Moreover, we showed that def-
icits in GABA levels do not ameliorate with age. Of
note, abnormalities in the GABA system in NF1 are
involved in relevant behavioral and cognitive domains
including social learning,26 memory,28 and inhibitory
control.5
In sum, our results point to abnormalities in the
GABA system suggestive of synapthopathy, with both
pre- and postsynaptic involvement.
However, given the discrete distribution of
GABAA receptor abnormalities, it is difficult to sup-
port that treatments with GABAA antagonists, as sug-
gested from the animal literature,4 would be useful to
treat cognitive deficits in humans.
Figure 4 Cross-modality correlations between magnetic resonance spectroscopy and PET
(A) Results for the occipital voxel and (B) for the FEF voxel, for patients with NF1 (green) and controls (gray). The triangle
shape indicates a patient with NF1 in whommeasurements were performed in the left hemisphere and the white-filled circle
represents a patient in whom the FEF location was determined using anatomical landmarks. In patients with NF1, the con-
centration of GABA1 was negatively correlated with the density of GABA type A receptors in the FEF (r 5 20.842, p 5
0.004, n 5 9, 95% confidence interval 5 21.000 to 20.368 calculated from 10,000 bootstrap samples). BP 5 binding
potential; FEF 5 frontal eye field; GABA 5 g-aminobutyric acid; NF1 5 neurofibromatosis type 1.
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